Switch theme
Sign up to access all valuation multiples
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
1997
19
LTM Revenue n/a
LTM EBITDA n/a
$20.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Valerio Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Valerio Therapeutics achieved revenue of $1.9M and an EBITDA of -$19.8M.
Valerio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valerio Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $1.9M | XXX | XXX | XXX |
| Gross Profit | $4.0M | $1.0M | XXX | XXX | XXX |
| Gross Margin | 256% | 52% | XXX | XXX | XXX |
| EBITDA | -$18.3M | -$19.8M | XXX | XXX | XXX |
| EBITDA Margin | -1184% | -1025% | XXX | XXX | XXX |
| Net Profit | -$6.4M | -$21.0M | XXX | XXX | XXX |
| Net Margin | -411% | -1087% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Valerio Therapeutics's stock price is EUR 0 (or $0).
Valerio Therapeutics has current market cap of EUR 9.6M (or $10.3M), and EV of EUR 18.8M (or $20.2M).
See Valerio Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.2M | $10.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Valerio Therapeutics has market cap of $10.3M and EV of $20.2M.
Valerio Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Valerio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Valerio Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $20.2M | XXX | XXX | XXX |
| EV/Revenue | 10.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.0x | XXX | XXX | XXX |
| P/E | -0.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpValerio Therapeutics's NTM/LTM revenue growth is n/a
Valerio Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Valerio Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Valerio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Valerio Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1025% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 145% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 538% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1129% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valerio Therapeutics acquired XXX companies to date.
Last acquisition by Valerio Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Valerio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Valerio Therapeutics founded? | Valerio Therapeutics was founded in 1997. |
| Where is Valerio Therapeutics headquartered? | Valerio Therapeutics is headquartered in France. |
| How many employees does Valerio Therapeutics have? | As of today, Valerio Therapeutics has 19 employees. |
| Is Valerio Therapeutics publicy listed? | Yes, Valerio Therapeutics is a public company listed on PAR. |
| What is the stock symbol of Valerio Therapeutics? | Valerio Therapeutics trades under ALVIO ticker. |
| When did Valerio Therapeutics go public? | Valerio Therapeutics went public in 2005. |
| Who are competitors of Valerio Therapeutics? | Similar companies to Valerio Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Valerio Therapeutics? | Valerio Therapeutics's current market cap is $10.3M |
| What is the current revenue growth of Valerio Therapeutics? | Valerio Therapeutics revenue growth between 2023 and 2024 was 25%. |
| Is Valerio Therapeutics profitable? | Yes, Valerio Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
